Diagnostic criteria for adult T-cell leukemia/lymphoma are not certified in this knowledge packet beyond the documented etiologic association with HTLV-1 infection and the classification as a peripheral T-cell neoplasm.

No approved treatments are certified in this knowledge packet for adult T-cell leukemia/lymphoma. Active clinical trials with ATLL-specific enrollment include: a Phase 1/2 study of OJP-001 in patients with ATLL (NCT07075328, sponsored by Otsuka Medical Devices, Japan, completion anticipated 2028); a Phase 2 study of mogamulizumab combined with chemotherapy in aggressive T-cell lymphoma including ATLL (NCT05996185, Yale University, completion 2027); a Phase 2 study evaluating mogamulizumab for prevention of ATLL in HTLV-1-infected individuals (NCT06698003, Memorial Sloan Kettering Cancer Center, completion 2029); and a Phase 1 study of natural killer cell therapy combined with mogamulizumab (NCT04848064, completion 2027). Trial intervention categories include drug therapy, biologic therapy, and procedural interventions.

Prognosis data for adult T-cell leukemia/lymphoma are not certified in this knowledge packet beyond the documented prevalence estimate of 1–9 per 100,000 individuals. Natural history data are not available in this packet.

Two hundred twenty-two classified publications document research activity in adult T-cell leukemia/lymphoma, with Basic Science and Preclinical research as the dominant type. Review literature (44 reviews) and case reports (33) are also substantial. Active clinical investigations include ATLL-specific registries (NCT05978141 at Memorial Sloan Kettering, NCT01137825 at UNC Lineberger), observational characterization studies (NCT05237245, HTLV-1-infected individuals and ATLL patients, Assistance Publique-Hopitaux de Paris), and therapeutic trials targeting ATLL-specific pathways (NCT07075328, NCT06698003, NCT04848064). Stem cell transplantation approaches are also under investigation (NCT00544115, NCT07356245). Gene therapy-related publications are represented in the research landscape.